WOCKPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.2
| Stock Code | WOCKPHARMA | Market Cap | 25,577 Cr. | Current Price | 1,575 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 87.6 | Book Value | 190 ₹ | Dividend Yield | 0.00 % | ROCE | 9.74 % |
| ROE | 9.99 % | Face Value | 5.00 ₹ | DMA 50 | 1,452 ₹ | DMA 200 | 1,397 ₹ |
| Chg in FII Hold | 0.09 % | Chg in DII Hold | 0.41 % | PAT Qtr | 132 Cr. | PAT Prev Qtr | 38.0 Cr. |
| RSI | 57.9 | MACD | 57.4 | Volume | 5,56,785 | Avg Vol 1Wk | 11,69,483 |
| Low price | 1,087 ₹ | High price | 1,870 ₹ | PEG Ratio | 1.81 | Debt to equity | 0.64 |
| 52w Index | 62.4 % | Qtr Profit Var | 230 % | EPS | 19.5 ₹ | Industry PE | 30.5 |
📊 Chart Patterns & Trend: WOCKPHARMA is trading above both its 50 DMA (1,452 ₹) and 200 DMA (1,397 ₹), confirming strong bullish momentum. Price action shows an uptrend with consolidation near the 1,870 ₹ high. Trend bias remains positive.
📈 Moving Averages: Current price (1,575 ₹) is comfortably above both DMA levels, reinforcing bullish undertone. Sustained trading above 1,550 ₹ strengthens outlook.
⚖️ RSI: At 57.9, RSI is neutral-to-positive, suggesting room for further upside without being overbought.
📉 MACD: Strongly positive at 57.4, confirming bullish undertone and signaling continuation of upward momentum.
📊 Bollinger Bands: Price is near the upper band, indicating strong buying interest. Minor pullbacks may occur before further breakout.
📦 Volume Trends: Current volume (5,56,785) is lower than 1-week average (11,69,483), showing reduced participation despite price strength.
🎯 Entry Zone: 1,520–1,550 ₹ (near 50 DMA support).
🚪 Exit Zone: 1,800–1,870 ₹ (near resistance and 52-week high).
📌 Momentum Signal: Short-term bullish trend with consolidation near highs. A breakout above 1,870 ₹ could trigger fresh rally.
Positive
- ✅ Strong ROCE (9.74%) and ROE (9.99%) reflect improving efficiency.
- ✅ EPS at 19.5 ₹ supports valuation strength.
- ✅ PAT surged from 38 Cr. to 132 Cr. quarter-on-quarter.
- ✅ PEG ratio at 1.81 indicates growth prospects are reasonably aligned with valuation.
Limitation
- ⚠️ High P/E (87.6) compared to industry PE (30.5) suggests steep overvaluation.
- ⚠️ Debt-to-equity at 0.64 is relatively high, adding financial risk.
- ⚠️ Dividend yield at 0.00% limits income appeal.
Company Negative News
- 📉 Stock corrected from 52-week high (1,870 ₹) to current levels near 1,575 ₹.
- 📉 Volume participation is lower than average, raising caution on sustainability of momentum.
Company Positive News
- 📈 DII holdings increased by 0.41%, reflecting strong domestic institutional support.
- 📈 FII holdings increased slightly by 0.09%, showing foreign investor confidence.
- 📈 Quarterly profit variation at 230% highlights strong earnings momentum.
- 📈 Stock has delivered strong 52-week performance (62.4%).
Industry
- 🏭 Industry PE at 30.5 indicates sector is moderately valued compared to WOCKPHARMA’s premium valuation.
- 🏭 Pharma sector outlook remains strong, driven by global demand and regulatory approvals.
Conclusion
🔎 WOCKPHARMA is in a bullish trend with consolidation near highs. Entry near 1,520–1,550 ₹ offers favorable risk-reward, while resistance at 1,800–1,870 ₹ should be watched for exits. A breakout above 1,870 ₹ could trigger fresh upside momentum. Investors should monitor volume strength and debt levels for confirmation of sustained rally.